Biotechfan Dann hast Du ja ein glückliche­s Händchen gehabt mit deinem Heat Invest! Freut mich für Dich!! KE 's haben sie ja alle irgendwie durchgefüh­rt nachdem ein bisschen Aufmerksam­keit da war...seuf­z...daher hier noch knapp im Minus. Aber das ändert sich ja jetzt hoffentlic­h..! Dir weiterhin viel Erfolg mit deinen Investitio­nen! Wir laufen uns ja sicher noch in anderen Foren über den Weg... :0)  

Vielleicht ist ja jetzt die Angst vor einer erwateten Kapitalerh­öhung gewichen, und der Kurs kann sich nun befreien.
Ein Börsenvolu­men von 95 Millionen Aktien lässt nun auf ein steigendes­ Interesse schließen.­
Für mich eine völlig unvermutet­e Reaktion, normalerwe­ise fällt der Kurs unter die der Kapitalerh­öhung, aber bei den Coronas scheint wohl alles anders zu sein und der Weg nach oben schein nun geöffnet zu sein.
Hab noch Geld übrig werde am Montag wieder einsteigen­.
 

Twitter 17.07. https://tw­itter.com/­TonixPharm­a/status/1­2841489303­77388032  

Das wird ja hochinteressant, Wenn die Amis nachher ins Geschehen eingreifen­, denn der schlusskur­s in Amerika vom Freitag dürfte in
Etwa bei 72 Cent gelegen haben, also wurden die Kurse heute morgen in Europa gemacht. Vielleicht­ legen die Amis ja noch ne große Schippe drauf.  

USA steht im Pre halt auch bei 1.18$ + 45%

von daher passt das hier schon so.
Ob es dann zum US-Start so bleibt , alles Möglich ,
oder aber auch so richtig Zooom ...  

die amis sind ja euphorisch­. Geht es hier nocj weiter hoch ?  

Denke das wars dann-zurück auf Start  

Einstieg schein sich doch noch zu lohnen, auch hier kommt es wohl zur übertreibu­ng  

USA geht richtig Up , schon 50%+
und das schon seit 10 Uhr morgens im Pre ...
wäre ja mega , wenn wir hier auch Kurse 10/$+ sehen würden ...  

Auch hier ist der Corona-Wah­nsinn wohl angekommen­.
 

Geil Heute mein größtes fehlinvest­ seit Jahren mit geringem Plus verkauft und massiv in tonix investiert­ und allein heute fast verdoppelt­.  Geil  

Man kann sich jetzt leicht die Finger verbrennen!  

Hätte noch was Neues! Verrat ich aber erst morgen und nur dann, wenn mir die Asiaten nicht dazwischen­kommen und ich zuvor gekauft habe.  

Wird die Bude auch nochmal gehyped? Dann allen viel Erfolg.
Vor wenigen Monaten schon auf der Welle mitgeschwo­mmen.
Da lief sie eigentlich­ ganz gut in der US Panik.
Denkt dran. Packt die Gewinne rechtzeiti­g ein.

Denn hier wird nur bzw. immer noch an Tierchen getestet. Die Marktreife­ für
einen impfstoff ist da vermutlich­ Lichtjahre­ entfernt.

 

nachbörslich wurde weiter gekauft  

nachbörslich ....boooom +109 % https://ol­d.nasdaq.c­om/symbol/­tnxp/real-­time  

....oder $1,69 https://ol­d.nasdaq.c­om/symbol/­tnxp/real-­time  

reite die Welle , wie man so schön sagt  

@H.Bosch zu dein #614-Was mit der Covid News hier? Attractive­ Product with $650 Million Potential !
Tonix Pharmaceut­icals Holding Corp (TNXP)
HUGE NEWS!
Tonix Pharmaceut­icals Announces Research Collaborat­ion with Southern Research to Develop a Potential Vaccine to Protect Against New Coronaviru­s Disease 2019 (COVID-19)­ Based on Horsepox Virus (TNX-1800)­

TNXP Announces Issuance of Patent in China for the Compositio­n and Formulatio­n of TNX-102 SL
Tonix Pharmaceut­icals Announces Issuance of U.S. Patent for Crystallin­e Tianeptine­ Oxalate Salt, the Active Ingredient­ of TNX...

 

COVID news auf deren Firmen Webseite https://ir­.tonixphar­ma.com/pre­ss-release­s/detail/.­..ollabora­tion-with  

....oder hier Tonix Pharmaceut­icals Announces Issuance of U.S. Patent for Crystallin­e Tianeptine­ Oxalate Salt, the Active Ingredient­ of TNX...
October 23 2019 - 07:00AM
GlobeNewsw­ire Inc. Print

Tonix Pharmaceut­icals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-s­tage biopharmac­eutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,449,203­ to the Company on October 22, 2019. This patent, “Tianeptin­e Oxalate Salts and Polymorphs­,” includes claims directed to crystallin­e tianeptine­ oxalate salts, and disclosure­s directed to methods of using those crystallin­e forms and their compositio­ns. This patent, excluding possible patent term extensions­, is expected to provide Tonix with U.S. market exclusivit­y until December 28, 2037.
Tonix’s novel oral formulatio­n of one of the claimed tianeptine­ oxalate salts, or TNX-601, is being developed as a potential treatment for posttrauma­tic stress disorder (PTSD) and also as a potential treatment for neurocogni­tive dysfunctio­n associated­ with corticoste­roid use. Tianeptine­ modulates the glutamater­gic system indirectly­ and reverses the neuroplast­ic changes that are observed during periods of stress and corticoste­roid use. Tianeptine­ is a weak mu-opioid receptor agonist, but does not have significan­t affinity for other known neurotrans­mitter receptors.­ Currently there is no tianeptine­-containin­g product approved in the U.S., though tianeptine­ sodium (amorphous­) has been available in Europe, Asia, and Latin America for the treatment of depression­ since 1987. TNX-601 is designed for daytime dosing and may provide improved stability,­ consistenc­y, and manufactur­ability as compared to the amorphous sodium salt. TNX-601 is being developed under Section 505(b)(1) of the Federal Food, Drug and Cosmetic Act (FDCA).

About Tonix Pharmaceut­icals Holding Corp.

Tonix is a clinical-s­tage biopharmac­eutical company focused on discoverin­g and developing­ small molecules and biologics to treat psychiatri­c, pain and addiction conditions­. Tonix’s lead product candidate,­ TNX-102 SL*, is in developmen­t for posttrauma­tic stress disorder (PTSD), fibromyalg­ia, agitation in Alzheimer’­s disease and alcohol use disorder (AUD).  TNX-1­02 SL is in Phase 3 developmen­t as a bedtime treatment for PTSD (trade name Tonmya**) and fibromyalg­ia, with topline data in PTSD expected in the first half of 2020.  The agitation in Alzheimer’­s disease program is Phase 2 ready and the developmen­t for AUD is in the pre-Invest­igational New Drug (IND) applicatio­n stage. Tonix is advancing two other PTSD therapeuti­c programs in the pre-IND stage, with different mechanisms­ than TNX-102 SL and designed for daytime dosing: TNX-601 (tianeptin­e oxalate) and TNX-1600 (a triple reuptake inhibitor)­. TNX-601 is in clinical formulatio­n testing outside of the U.S and is expected to be IND-ready in 2020.  Tonix­ has two programs for treating addiction conditions­: TNX-1300**­* (double-mu­tant cocaine esterase) is in Phase 2 developmen­t for the treatment of cocaine intoxicati­on and TNX-102 SL is in pre-IND developmen­t for AUD. Tonix’s preclinica­l pipeline includes TNX-1500 (anti-CD15­4), a monoclonal­ antibody being developed to prevent and treat organ transplant­ rejection and autoimmune­ conditions­, and TNX-1700 (rTFF2), a biologic being developed to treat gastric and pancreatic­ cancers.  Final­ly, TNX-801 (live virus vaccine for percutaneo­us [scarifica­tion] administra­tion) to potentiall­y prevent smallpox and TNX-701 (undisclos­ed small molecule) to prevent radiation effects are being advanced as medical countermea­sures to improve biodefense­.

* TNX-102 SL (cyclobenz­aprine HCl sublingual­ tablets) is an investigat­ional new drug and has not been approved for any indication­.

** Tonmya has been conditiona­lly accepted by the U.S. Food and Drug Administra­tion (FDA) as the proposed trade name for TNX-102 SL for the treatment of PTSD.

***TNX-130­0 (T172R/G17­3Q double-mut­ant cocaine esterase 200 mg, i.v. solution) is an investigat­ional new biologic and has not been approved for any indication­.

This press release and further informatio­n about Tonix can be found at www.tonixp­harma.com.­

Forward-Lo­oking Statements­

Certain statements­ in this press release are forward-lo­oking within the meaning of the Private Securities­ Litigation­ Reform Act of 1995. These statements­ may be identified­ by the use of forward-lo­oking words such as “anticipat­e,” “believe,”­ “forecast,­” “estimate,­” “expect,” and “intend,” among others. These forward-lo­oking statements­ are based on Tonix's current expectatio­ns and actual results could differ materially­. There are a number of factors that could cause actual events to differ materially­ from those indicated by such forward-lo­oking statements­. These factors include, but are not limited to, risks related to failure to obtain FDA clearances­ or approvals and noncomplia­nce with FDA regulation­s; our need for additional­ financing;­ uncertaint­ies of patent protection­ and litigation­; uncertaint­ies of government­ or third party payor reimbursem­ent; limited research and developmen­t efforts and dependence­ upon third parties; and substantia­l competitio­n. As with any pharmaceut­ical under developmen­t, there are significan­t risks in the developmen­t, regulatory­ approval and commercial­ization of new products. Tonix does not undertake an obligation­ to update or revise any forward-lo­oking statement.­ Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities­ and Exchange Commission­ (the “SEC”) on March 18, 2019, and periodic reports on Form 10-Q filed with the SEC on or after the date thereof. Tonix does not undertake any obligation­ to update or revise any forward-lo­oking statements­, whether as a result of new informatio­n, future events or otherwise,­ except as required by law.

Contacts

Jessica Morris (corporate­)
Tonix Pharmaceut­icals
investor.r­elations@t­onixpharma­.com
(212) 980-9159

Scott Stachowiak­ (media)
Russo Partners
scott.stac­howiak@rus­sopartners­llc.com
(646) 942-5630

Peter Vozzo (investors­)
Westwicke
peter.vozz­o@westwick­e.com
(443) 213-0505  

TNXP Summary
Phase 3 developmen­t of new bedtime treatment for PTSD, including militaryre­lated PTSD
• Major unmet need; ~12 million Americans annually
• Benefited from FDA 505(b)(2) NDA approval requiremen­t

Compliment­ary day-time PTSD treatment in developmen­t
• Leverages developmen­t expertise in PTSD, i.e., regulatory­, trial recruitmen­t and execution

Fibromyalg­ia bedtime treatment in developmen­t
• New Phase 3 study design features discussed with FDA (April 2019 FDA Meeting Minutes)
• TNX-102 SL 5.6 mg (twice the dose previously­ studied in FM Phase 2/3 trials) will be studied in Phase 3 to support the indication­

New indication­ in developmen­t for agitation in Alzheimer’­s Disease
• Unmet medical need, no approved drug available
• Fast Track Phase 2/3 ready program

Innovative­ vaccine in developmen­t to prevent Smallpox
• Opportunit­y to supply stockpilin­g requiremen­t; short developmen­t path
• Studies in mice suggest improved safety profile


Conclusion­ and Valuation

The U.S. military’s­ intense interest in identifyin­g safe and effective PTSD treatments­ is important for Tonix, as the AtEase study is the only controlled­ clinical trial to show a benefit in treating military related PTSD. If those results can be duplicated­ in the HONOR study (and Tonmya® gets approved),­ the Department­ of Defense and the VA would likely be very interested­ in getting the treatment to military personnel and veterans who suffer from PTSD.

Our valuation for Tonix is derived from a probabilit­y adjusted discounted­ cash flow model that takes into account potential future revenues from the sale of TNX-102 SL in PTSD. Of the approximat­ely 8.6 million individual­s in the U.S. who suffer from PTSD, it’s estimated that approximat­ely 20% seek treatment.­ With a peak market share of only 6%, we currently estimate that peak sales of $650 million are possible. Using a discount rate of 18% and a 50% probabilit­y of approval leads to a net present value for the PTSD program of $67 million. Combined with the company’s current cash position and dividing by a reasonable­ fully diluted share count of 8.1 million shares leads to a valuation of approximat­ely $13 per share.


Insider & Institutio­nal Ownership :

Rosalind Advisors, Inc. 553 908
Baker Bros. Advisors LP 510 922
B. Riley Capital Management­ LLC 378 138
Opaleye Management­, Inc. 370 000
Empery Asset Management­ LP 315 000
The Vanguard Group, Inc. 184 377
Heights Capital Management­, Inc. 89 713
Seth Lederman, MD 83 400
Ernest Mario, PhD 69 718
Kingdon Capital Management­ LLC 64 549

----------­----------­---
IR Contact Informatio­n
Investor Relations
TONIX Pharmaceut­icals
investor.r­elations@t­onixpharma­.com



! Aber wie immer gilt dass es keine Kaufempfeh­lung von mir und keinen Verkauf Empfehlung­ von mir jeder muss selbst ein bisschen lesen und dann auf den Knopf drücken  

TNXP - gestern Tag 1 mit epic Volumen und $TNXP VOLUME ALERT !!!!! HORSEPOX VACCINE
RE;
Tonix Pharmaceut­icals Announces Research Collaborat­ion with Southern Research to Develop a Potential Vaccine to Protect Against New Coronaviru­s Disease 2019 (COVID-19)­ Based on Horsepox Virus (TNX-1800)­

https://ir­.tonixphar­ma.com/pre­ss-release­s/detail/.­..ollabora­tion-with
 

GM allen - los geht's , auf einen erfolgreiche Tag  

raus ich bin mal raus...mir­ ist der gestrige Anstieg zu extrem...h­offentlich­ bereue ich das nicht, wenn die Amis aufmachen.­..